Department of Chemical and Systems Biology, ChEM-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA; SPARK Translational Research Program, Stanford University School of Medicine, Stanford, CA, USA.
Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Eur J Med Chem. 2024 Dec 5;279:116904. doi: 10.1016/j.ejmech.2024.116904. Epub 2024 Sep 24.
Chemically induced proximity modalities such as targeted protein degradation (TPD) hold promise for expanding the number of proteins that can be manipulated pharmacologically. However, current TPD strategies are often limited to proteins with preexisting ligands. Molecular glues (e.g. glutarimide ligands for CUL4), offer the potential to target undruggable proteins. Yet, their rational design is largely unattainable due to the unpredictability of the 'gain-of-function' nature of the glue interaction upon chemical modification of ligands. We recently reported a covalent trans-labelling glue mechanism which we named 'Template-assisted covalent modification', where an electrophile decorated BRD4 inhibitor was effectively delivered to a cysteine residue on DCAF16 due to an electrophile-induced BRD4-DCAF16 interaction. Herein, we report our efforts to evaluate how various electrophilic modifications to the BRD4 binder, JQ1, affect DCAF16 recruitment and subsequent BRD4 degradation efficiency. We discovered a moderate correlation between the electrophile-induced BRD4-DCAF16 ternary complex formation and BRD4 degradation. Moreover, we show that a more solvent-exposed warhead presentation optimally recruits DCAF16 and promotes BRD4 degradation. The diversity of covalent attachments in this class of BRD4 degraders suggests a high tolerance and tunability for the BRD4-DCAF16 interaction. This offers a new avenue for rational glue design by introducing covalent warheads to known binders.
化学诱导的邻近模式,如靶向蛋白降解(TPD),有望扩大可通过药理学手段操纵的蛋白质数量。然而,目前的 TPD 策略通常仅限于具有预先存在配体的蛋白质。分子胶(例如,CUL4 的戊二酰亚胺配体)具有靶向不可成药蛋白的潜力。然而,由于配体化学修饰后胶相互作用的“功能获得”性质不可预测,其合理设计在很大程度上无法实现。我们最近报道了一种共价反标记胶机制,我们称之为“模板辅助共价修饰”,其中带正电的 BRD4 抑制剂由于带正电的 BRD4-DCAF16 相互作用而有效地递送到 DCAF16 的半胱氨酸残基上。在此,我们报告了我们评估 BRD4 结合物 JQ1 的各种亲电修饰如何影响 DCAF16 募集和随后的 BRD4 降解效率的努力。我们发现,亲电诱导的 BRD4-DCAF16 三元复合物形成与 BRD4 降解之间存在中度相关性。此外,我们表明,更暴露于溶剂的弹头呈现方式最佳地募集 DCAF16 并促进 BRD4 降解。这类 BRD4 降解物中的共价连接的多样性表明 BRD4-DCAF16 相互作用具有高耐受性和可调节性。通过向已知配体中引入共价弹头,为合理的胶设计提供了新途径。